Logo

PharmaShots Weekly Snapshots (October 24 - 28, 2022)

Share this
PharmaShots Weekly Snapshots (October 24 - 28, 2022)

PharmaShots Weekly Snapshots (October 24 - 28, 2022)

Pharming’s MAA Application for Leniolisib Receives Approval by the EMA to Treat Activated Phosphoinositide 3-Kinase Delta Syndrome

Published: Oct 28, 2022| Tags: Pharming, Leniolisib, Activated Phosphoinositide 3-Kinase Delta Syndrome, Regulatory, P-II, P-III, EMA

Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022

Published: Oct 28, 2022| Tags: Puma Biotechnology, Neratinib, EGFR Exon 18-Mutant NSCLC, Clinical Trial, P-II (SUMMIT) Basket Trial, EORTC, NCI, AACR, 2022

Sciwind Biosciences Reports P-IIb Trial Interim Results of XW003 (ecnoglutide) for the Treatment of Obesity

Published: Oct 28, 2022| Tags: Sciwind Biosciences, XW003, ecnoglutide, Obesity, Clinical Trial, P-IIb Trial

Mustang Bio Presented P-I/II Clinical Trial of MB-106 for Waldenstrom's Macroglobulinemia at 11th International Workshop

Published: Oct 28, 2022| Tags: Mustang Bio, MB-106, Waldenstrom's Macroglobulinemia, Clinical Trial, P-I/II Clinical Trial, 11th International Workshop

AstraZeneca Presents P-III (CHAMPION-NMOSD) Trial Results of Ultomiris (ravulizumab) for Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

Published: Oct 28, 2022| Tags: AstraZeneca, Ultomiris, ravulizumab, Neuromyelitis Optica Spectrum Disorder, Clinical Trial, P-III, CHAMPION-NMOSD Trial, ECTRIMS, 2022

ITM’s ITM-11 Receives the FTD by the US FDA for the Treatment of Neuroendocrine Tumors

Published: Oct 27, 2022| Tags: ITM, ITM-11, Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumors, Regulatory, P-III, COMPOSE, COMPETE

Janssen’s Tecvayli (teclistamab-cqyv) Receives the US FDA’s Approval for the Treatment of Relapsed or Refractory Multiple Myeloma

Published: Oct 27, 2022| Tags: Janssen, Tecvayli, teclistamab-cqyv, Multiple Myeloma, Regulatory, US, FDA, Approval

BIOCORP and Novo Nordisk Expands its 2021 Agreement to Commercialize Mallya Smart Sensor in Japan

Published: Oct 27, 2022| Tags: BIOCORP, Novo Nordisk, Mallya Smart Sensor, FlexTouch insulin pens, NovoPen 6, NovoPen Echo Plus, Pharma, Japan

Genentech Reports P-III (BALATON) and (COMINO) Studies Results of Vabysmo (faricimab-svoa) for the Treatment of Retinal Vein Occlusion

Published: Oct 27, 2022| Tags: Genentech, Vabysmo, faricimab-svoa, Retinal Vein Occlusion, Clinical Trial, P-III, BALATON, COMINO

AstraZeneca Reports Results of Capivasertib in P-III Trial for the Treatment of Advanced HR-positive Breast Cancer

Published: Oct 27, 2022| Tags: AstraZeneca, Capivasertib, Advanced HR-positive Breast Cancer, Clinical Trial, P-III, CAPItello-291

Bayer’s Kerendia (finerenone) Receives Health Canada’s Approval for the Treatment of Chronic Kidney Disease and Type 2 Diabetes

Published: Oct 27, 2022| Tags: Bayer, Kerendia, Chronic Kidney Disease, Type 2 Diabetes, Regulatory, P-III, FIDELIO-DKD, FIGARO-DKD

Merck Reports P-III Trial Results of Prevymis for the Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation

Published: Oct 25, 2022| Tags: Merck, Prevymis, Cytomegalovirus Disease, Kidney Transplantation, Clinical Trials, P-III Trial

Janssen Presents P-IIb (QUASAR) Induction Study Results of Tremfya (guselkumab) for Active Ulcerative Colitis at ACG 2022

Published: Oct 25, 2022| Tags: Janssen, Tremfya, guselkumab, Active Ulcerative Colitis, P-IIb (QUASAR) Induction Study at ACG 2022

Syncona to Acquire AGTC for ~$73.5M

Published: Oct 25, 2022| Tags: Syncona, AGTC, AGTC-501, X-linked retinitis pigmentosa, ~$73.5M, M&A

Sumitovant and Sumitomo to Acquire Myovant Sciences for ~$1.7B

Published: Oct 25, 2022| Tags: Sumitovant, Sumitomo, Myovant Sciences, prostate cancer, ~$1.7B, M&A

Novartis Reports P-III (APPLY-PNH) Trial Results of Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Published: Oct 25, 2022| Tags: Novartis, Iptacopan, Paroxysmal Nocturnal Hemoglobinuria, Clinical Trial, P-III APPLY-PNH Trial

AstraZeneca’s Imjudo (tremelimumab) + Imfinzi (durvalumab) Receive the US FDA’s Approval for Unresectable Liver Cancer

Published: Oct 25, 2022| Tags: AstraZeneca, Imjudo, tremelimumab, Imfinzi, durvalumab, Unresectable Liver Cancer, Regulatory, US, FDA, Approval

Related Post: PharmaShots Weekly Snapshots (October 17- 21, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions